These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27275103)

  • 1. Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients.
    Nakagawa A; Atsukawa M; Tsubota A; Kondo C; Okubo T; Arai T; Itokawa N; Narahara Y; Iwakiri K
    World J Gastroenterol; 2016 Jun; 22(21):5104-13. PubMed ID: 27275103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolvaptan for the treatment of liver cirrhosis oedema.
    Sakaida I
    Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):461-70. PubMed ID: 24678622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema.
    Atsukawa M; Tsubota A; Kato K; Abe H; Shimada N; Asano T; Ikegami T; Koeda M; Okubo T; Arai T; Nakagawa-Iwashita A; Yoshida Y; Hayama K; Itokawa N; Kondo C; Chuganji Y; Matsuzaki Y; Iwakiri K
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1256-1263. PubMed ID: 29215154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis.
    Kirnake V; Arora A; Sharma P; Goyal M; Chawlani R; Toshniwal J; Kumar A
    Indian J Gastroenterol; 2018 Jul; 37(4):335-341. PubMed ID: 30178093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.
    Zhang X; Wang SZ; Zheng JF; Zhao WM; Li P; Fan CL; Li B; Dong PL; Li L; Ding HG
    World J Gastroenterol; 2014 Aug; 20(32):11400-5. PubMed ID: 25170228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Tolvaptan on Fluid Management After Cardiovascular Surgery Using Cardiopulmonary Bypass.
    Ito H; Mizumoto T; Tempaku H; Fujinaga K; Sawada Y; Shimpo H
    J Cardiothorac Vasc Anesth; 2016 Dec; 30(6):1471-1478. PubMed ID: 27591907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response criteria of tolvaptan for the treatment of hepatic edema.
    Hiramine Y; Uojima H; Nakanishi H; Hiramatsu A; Iwamoto T; Kimura M; Kawaratani H; Terai S; Yoshiji H; Uto H; Sakaida I; Izumi N; Okita K; Koike K
    J Gastroenterol; 2018 Feb; 53(2):258-268. PubMed ID: 28664229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study.
    Jia JD; Xie W; Ding HG; Mao H; Guo H; Li Y; Wang X; Wang JF; Lu W; Li CZ; Mao Y; Wang GQ; Gao YQ; Wang B; Zhang Q; Ge Y; Wong VW
    Ann Hepatol; 2017; 16(1):123-132. PubMed ID: 28051801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictability of tricuspid annular plane systolic excursion for the effectiveness of tolvaptan in patients with heart failure.
    Niwa T; Waseda K; Mizuno T; Nakano Y; Mukai K; Wakabayashi H; Watanabe A; Ando H; Takashima H; Amano T
    J Echocardiogr; 2017 Sep; 15(3):118-126. PubMed ID: 28194742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study).
    Sakaida I; Terai S; Kurosaki M; Okada M; Hirano T; Fukuta Y
    J Gastroenterol; 2020 Aug; 55(8):800-810. PubMed ID: 32388692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis.
    Okita K; Sakaida I; Okada M; Kaneko A; Chayama K; Kato M; Sata M; Yoshihara H; Ono N; Murawaki Y
    J Gastroenterol; 2010 Sep; 45(9):979-87. PubMed ID: 20387081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
    Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
    Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study.
    La Mura V; Abraldes JG; Berzigotti A; Erice E; Flores-Arroyo A; García-Pagán JC; Bosch J
    Hepatology; 2010 Jun; 51(6):2108-16. PubMed ID: 20512998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis.
    Bruha R; Jachymova M; Petrtyl J; Dvorak K; Lenicek M; Urbanek P; Svestka T; Vitek L
    World J Gastroenterol; 2016 Mar; 22(12):3441-50. PubMed ID: 27022226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.
    Komiyama Y; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Yasui Y; Tamaki N; Takada H; Higuchi M; Gotou T; Kubota Y; Takaura K; Hayashi T; Oh W; Okada M; Enomoto N; Izumi N
    PLoS One; 2017; 12(3):e0174649. PubMed ID: 28362879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation and comparison of the model for end-stage liver disease, portal pressure, and serum sodium for outcome prediction in patients with liver cirrhosis.
    Wang YW; Huo TI; Yang YY; Hou MC; Lee PC; Lin HC; Lee FY; Chi CW; Lee SD
    J Clin Gastroenterol; 2007 Aug; 41(7):706-12. PubMed ID: 17667056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis.
    Reverter E; Blasi A; Abraldes JG; Martínez-Palli G; Seijo S; Turon F; Berzigotti A; Balust J; Bosch J; García-Pagán JC
    Liver Int; 2014 Jan; 34(1):16-25. PubMed ID: 23763484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small intestinal edema had the strongest correlation with portal venous pressure amongst capsule endoscopy findings.
    Takahashi Y; Fujimori S; Narahara Y; Gudis K; Ensaka Y; Kosugi Y; Maki K; Suzuki M; Matsushita Y; Fukuda T; Kanazawa H; Sakamoto C
    Digestion; 2012; 86(1):48-54. PubMed ID: 22710440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema.
    Atsukawa M; Tsubota A; Takaguchi K; Toyoda H; Iwasa M; Ikegami T; Chuma M; Nozaki A; Uojima H; Hiraoka A; Fukunishi S; Yokohama K; Tada T; Kato K; Abe H; Tani J; Okubo H; Watanabe T; Hattori N; Tsutsui A; Senoh T; Yoshida Y; Okubo T; Itokawa N; Nakagawa-Iwashita A; Kondo C; Arai T; Michitaka K; Iio E; Kumada T; Tanaka Y; Takei Y; Iwakiri K
    J Gastroenterol Hepatol; 2020 Jul; 35(7):1229-1237. PubMed ID: 31881554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease.
    Nagayama I; Masuda T; Nakagawa S; Murakami T; Ohara K; Matsuoka R; Kobayashi T; Maeshima A; Akimoto T; Saito O; Muto S; Nagata D
    Intern Med; 2019 Jun; 58(11):1587-1591. PubMed ID: 30713322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.